{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:05:25Z","timestamp":1790089525717,"version":"4.0.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.07.026","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:27:36Z","timestamp":1786544856000},"page":"1440-1449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2078","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jacc.2026.07.026_bib1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jacc.2026.07.026_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2026.07.026_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"kidney outcomes in transthyretin amyloid cardiomyopathy","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"14","key":"10.1016\/j.jacc.2026.07.026_bib4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacc.2026.07.026_bib5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2026.07.026_bib6","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamacardio.2024.2555","article-title":"Redefining cardiac involvement and targets of treatment in systemic immunoglobulin AL amyloidosis","volume":"9","author":"Porcari","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.jacc.2026.07.026_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2025.10.054","article-title":"Myocardial amyloid burden in transthyretin amyloidosis","volume":"87","author":"Sheikh","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"10038","key":"10.1016\/j.jacc.2026.07.026_bib8","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jacc.2026.07.026_bib9","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2\u2217 magnetic resonance for prediction of cardiac complications in thalassemia major","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacc.2026.07.026_bib10","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2\u2217 cardiovascular magnetic resonance","volume":"127","author":"Anderson","year":"2004","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2026.07.026","type":"removal","label":"Removal","source":"publisher","updated":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000}}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726072499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726072499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:31:16Z","timestamp":1790087476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726072499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0735109726072499"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.07.026","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking Disease Progression in Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}